Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.…
Qureight’s Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial
Contineum Therapeutics (NASDAQ: CTNM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 51 employees.
The shares were at 8.680 USD on 20 November 2026, down 20.5% over 52 weeks. Its 52-week range is 6.725 USD to 17.79 USD: the price is 51.2% below the high and 29.1% above the low.
Its market capitalisation is 340.83M USD.
Contineum Therapeutics reports return on equity of -23.0% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 238.22M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 7 analysts cover the stock, with an average rating of Buy; their mean price target of 21.43 USD is 146.9% above the current price. The next earnings report is expected on 4 March 2027.